menu ☰
menu ˟

Dicerna doses first patient in trial of RNA inhibitor for chronic HBV

17 May 2019
Dicerna dosed the first patient in a phase 1 clinical trial for DCR-HBVS, an investigational GalXCTM-based therapy for the treatment of chronic hepatitis B, according to a press release.“Dosing of the first patient in the DCR-HBVS-101 trial signals...

Click here to view the full article which appeared in Hepatology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.